Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyle Ferber

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 20, 2024
Dorsal root ganglion toxicity after AAV intra-CSF delivery of a RNAi expression construct into non-human primates and miceZachary C E Hawley, Ingrid D Pardo, Shaolong Cao, et al.
Cancer Discovery|January 28, 2021
An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor GrowthHubert Lam, Lisa K McNeil, Hanna Starobinets, et al.
Medrxiv : the Preprint Server for Health Sciences|November 22, 2024
Timing of changes in Alzheimer's disease plasma biomarkers as assessed by amyloid and tau PET clocksMarta Milà-Alomà, Duygu Tosun, Suzanne E Schindler, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 12, 2022
Comparative analytical performance of multiple plasma Aβ42 and Aβ40 assays and their ability to predict positron emission tomography amyloid positivityStephen Zicha, Randall J Bateman, Leslie M Shaw, et al.
Annals of Neurology|June 20, 2025
Timing of Changes in Alzheimer's Disease Plasma Biomarkers as Assessed by Amyloid and Tau PET ClocksMarta Milà-Alomà, Duygu Tosun, Suzanne E Schindler, et al.
Nature Medicine|February 19, 2026
Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocksKellen K Petersen, Marta Milà-Alomà, Yan Li, et al.
Nature Medicine|March 25, 2026
LRRK2-targeting antisense oligonucleotide in Parkinson's disease: a phase 1 randomized controlled trialOmar S Mabrouk, Ben Tichler, H Moore Arnold, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 20, 2024
Dorsal root ganglion toxicity after AAV intra-CSF delivery of a RNAi expression construct into non-human primates and miceZachary C E Hawley, Ingrid D Pardo, Shaolong Cao, et al.
Cancer Discovery|January 28, 2021
An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor GrowthHubert Lam, Lisa K McNeil, Hanna Starobinets, et al.
Medrxiv : the Preprint Server for Health Sciences|November 22, 2024
Timing of changes in Alzheimer's disease plasma biomarkers as assessed by amyloid and tau PET clocksMarta Milà-Alomà, Duygu Tosun, Suzanne E Schindler, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 12, 2022
Comparative analytical performance of multiple plasma Aβ42 and Aβ40 assays and their ability to predict positron emission tomography amyloid positivityStephen Zicha, Randall J Bateman, Leslie M Shaw, et al.
Annals of Neurology|June 20, 2025
Timing of Changes in Alzheimer's Disease Plasma Biomarkers as Assessed by Amyloid and Tau PET ClocksMarta Milà-Alomà, Duygu Tosun, Suzanne E Schindler, et al.
Nature Medicine|February 19, 2026
Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocksKellen K Petersen, Marta Milà-Alomà, Yan Li, et al.
Nature Medicine|March 25, 2026
LRRK2-targeting antisense oligonucleotide in Parkinson's disease: a phase 1 randomized controlled trialOmar S Mabrouk, Ben Tichler, H Moore Arnold, et al.
Pageof 2